Can I Succeed as a Freelance Regulatory Writer Without Industry Experience?

Biotech Ink Spots

Because I keep getting asked this question, I’m going to address it very directly in this post. I know there are many folks who want to do regulatory writing, but they don’t want to have to get a job in the drug industry to accomplish this goal. For those of you who have medical backgrounds, in particular, I certainly understand your position.

However, becoming a successful freelance (contract) medical writer is extremely difficult, if not impossible, without industry experience.

It gets down to this: you can’t write well about something you don’t understand, and you must have a reasonably thorough understanding of the drug/biologic development process in order to write clinical and regulatory documents about it. (I’ve covered this issue in more detail in my article, “What It Takes to Be a Medical Writer”.)

In the future, there may be numerous books that can teach you the things you learn when…

View original post 432 more words

Should I take Statins?

Coronary heart disease, heart attacks, and ischemic stroke are examples of cardiovascular disease (CVD). CVD is the main cause of mortality in the world and researchers are constantly investigating ways to treat the underlying causes of this disease. On 15 November, the US Preventive Services Task Force (USPSTF) released an updated recommendation for statin use … Continue reading Should I take Statins?

Candidates on Science

modified from: As scientists, we worry about how the election will affect the progression of science and funding for research. Much of the funding for science is through federal grants and organizations like the Department of Energy and NOAA. Therefore, the available funding for research could depend on President’s desire to see research funded. … Continue reading Candidates on Science

Life Science Tennessee Conference 2016 (Opening Session)

The conference was kicked off with a talk from Jim Greenwood, President and CEO of Biotechnology Innovation Organization. He talked about the benefits of technologies and lamented the fact that some give the industry a bad name by charging exorbitantly high prices for certain drugs. He continued to talk about the innovations and benefits that … Continue reading Life Science Tennessee Conference 2016 (Opening Session)